Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Visentin

Showing results (131-140 of 193) with videos related to

Pageof 20
Sort By:
British Journal of Haematology|July 30, 2022
Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 studyVincenzo Marasco, Alfonso Piciocchi, Anna Candoni, et al.
Haematologica|June 7, 2021
The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformationAndrea Visentin, Laura Bonaldi, Gian Matteo Rigolin, et al.
British Journal of Cancer|June 19, 2019
The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemiaAndrea Visentin, Laura Bonaldi, Gian Matteo Rigolin, et al.
Blood Advances|July 5, 2022
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian studyAlberto Fresa, Francesco Autore, Alfonso Piciocchi, et al.
American Journal of Hematology|December 14, 2021
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL studyAndrea Visentin, Francesca Romana Mauro, Francesca Cibien, et al.
Hemasphere|July 14, 2025
Predicting thrombotic risk in patients with classical Hodgkin lymphoma: Thro-HL multicenter studyGiovanni Manfredi Assanto, Eleonora Alma, Alessandro Cellini, et al.
Journal of Clinical Medicine|January 11, 2025
Predictors of Splenectomy Response in Immune Thrombocytopenia: A Multicentric Italian StudySimone Zoletto, Marco Pizzi, Andrea De Crescenzo, et al.
American Journal of Hematology|February 12, 2024
Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM studyFrancesco Autore, Andrea Visentin, Marina Deodato, et al.
American Journal of Hematology|October 7, 2017
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centersSilvia Cantoni, Monica Carpenedo, Maria Gabriella Mazzucconi, et al.
Leukemia & Lymphoma|March 28, 2022
How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemiaMarina Deodato, Anna Maria Frustaci, Paolo Sportoletti, et al.
Pageof 20

Showing results (131-140 of 193) with videos related to

Sort By:
Pageof 20
British Journal of Haematology|July 30, 2022
Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 studyVincenzo Marasco, Alfonso Piciocchi, Anna Candoni, et al.
Haematologica|June 7, 2021
The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformationAndrea Visentin, Laura Bonaldi, Gian Matteo Rigolin, et al.
British Journal of Cancer|June 19, 2019
The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemiaAndrea Visentin, Laura Bonaldi, Gian Matteo Rigolin, et al.
Blood Advances|July 5, 2022
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian studyAlberto Fresa, Francesco Autore, Alfonso Piciocchi, et al.
American Journal of Hematology|December 14, 2021
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL studyAndrea Visentin, Francesca Romana Mauro, Francesca Cibien, et al.
Hemasphere|July 14, 2025
Predicting thrombotic risk in patients with classical Hodgkin lymphoma: Thro-HL multicenter studyGiovanni Manfredi Assanto, Eleonora Alma, Alessandro Cellini, et al.
Journal of Clinical Medicine|January 11, 2025
Predictors of Splenectomy Response in Immune Thrombocytopenia: A Multicentric Italian StudySimone Zoletto, Marco Pizzi, Andrea De Crescenzo, et al.
American Journal of Hematology|February 12, 2024
Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM studyFrancesco Autore, Andrea Visentin, Marina Deodato, et al.
American Journal of Hematology|October 7, 2017
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centersSilvia Cantoni, Monica Carpenedo, Maria Gabriella Mazzucconi, et al.
Leukemia & Lymphoma|March 28, 2022
How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemiaMarina Deodato, Anna Maria Frustaci, Paolo Sportoletti, et al.
Pageof 20